TY - JOUR
T1 - Altered immunoglobulin profiles in children with Tourette syndrome
AU - Bos-Veneman, Netty G.P.
AU - Olieman, Renske
AU - Tobiasova, Zuzana
AU - Hoekstra, Pieter J.
AU - Katsovich, Lily
AU - Bothwell, Alfred L.M.
AU - Leckman, James F.
AU - Kawikova, Ivana
N1 - Funding Information:
The research was supported by Tourette’s Syndrome Association (IK), National Institute of Health Grant Nos. MH066187 , P01MH049351 (JFL), R01MH061940 (JFL), R01NS42240 , MH014235 , K05 MH076273 (JFL), M01RR006022 , and RR00125 . Dr. Olieman was supported during her stay at Yale University by Groningen University Funds, Marco Polo Scholarship and Tourette’s Syndrome Association. Dr. Tobiasova was supported by Tourette’s Syndrome Association and by the Czech Ministry of Education (MSM 00211620812). Support of James F. Leckman for the past three years: NIH (salary and research funding), Tourette Syndrome Association (research funding), Klingenstein Third Generation Foundation (medical student fellowship program), John Wiley and Sons (book royalties), McGraw Hill (book royalties), Oxford University Press (book royalties). Other authors do not claim any conflict of interest.
PY - 2011/3
Y1 - 2011/3
N2 - Background: Post-infectious autoimmunity and immune deficiency have been implicated in the pathogenesis of Tourette syndrome (TS). We asked here whether B cell immunity of patients with TS differs from healthy subjects. Methods: In two independent cross-sectional samples, we compared serum levels of IgG1, IgG2, IgG3, IgG4, IgM, IgA, and IgE in 21 patients with TS from Yale University (17 males, 4 females, 8-16. years) versus 21 healthy controls (13 males, 8 females, 7-17. years); and in 53 patients with TS from Groningen University (45 males, 8 females, 6-18. years) versus 53 healthy controls (22 males, 31 females, 6-18. years), respectively. We also investigated correlations between Ig concentrations and symptom severity. In 13 additional patients (9 males, 4 females, age range 9-14), we established Ig profiles at time points before, during, and after symptom exacerbations. Results: IgG3 levels were significantly lower in Yale patients compared to healthy children (medians 0.28 versus 0.49. mg/ml, p= .04), while levels of IgG2, IgG4, and IgM in patients were lower at trend-level significance (p≤ .10). Decreased IgG3 (medians 0.45 versus 0.52. mg/ml; p= .05) and IgM (medians 0.30 versus 0.38. mg/ml; p= .04) levels were replicated in the Groningen patients. Ig levels did not correlate with symptom severity. There was a trend-level elevation of IgG1 during symptom exacerbations (p= .09). Conclusion: These pilot data indicate that at least some patients with TS have decreased serum IgG3, and possibly also IgM levels, though only few subjects had fully expressed Ig immunodeficiency. Whether these changes are related to TS pathogenesis needs to be investigated.
AB - Background: Post-infectious autoimmunity and immune deficiency have been implicated in the pathogenesis of Tourette syndrome (TS). We asked here whether B cell immunity of patients with TS differs from healthy subjects. Methods: In two independent cross-sectional samples, we compared serum levels of IgG1, IgG2, IgG3, IgG4, IgM, IgA, and IgE in 21 patients with TS from Yale University (17 males, 4 females, 8-16. years) versus 21 healthy controls (13 males, 8 females, 7-17. years); and in 53 patients with TS from Groningen University (45 males, 8 females, 6-18. years) versus 53 healthy controls (22 males, 31 females, 6-18. years), respectively. We also investigated correlations between Ig concentrations and symptom severity. In 13 additional patients (9 males, 4 females, age range 9-14), we established Ig profiles at time points before, during, and after symptom exacerbations. Results: IgG3 levels were significantly lower in Yale patients compared to healthy children (medians 0.28 versus 0.49. mg/ml, p= .04), while levels of IgG2, IgG4, and IgM in patients were lower at trend-level significance (p≤ .10). Decreased IgG3 (medians 0.45 versus 0.52. mg/ml; p= .05) and IgM (medians 0.30 versus 0.38. mg/ml; p= .04) levels were replicated in the Groningen patients. Ig levels did not correlate with symptom severity. There was a trend-level elevation of IgG1 during symptom exacerbations (p= .09). Conclusion: These pilot data indicate that at least some patients with TS have decreased serum IgG3, and possibly also IgM levels, though only few subjects had fully expressed Ig immunodeficiency. Whether these changes are related to TS pathogenesis needs to be investigated.
KW - Immunoglobulin
KW - Symptom exacerbation
KW - Tic disorder
KW - Tourette syndrome
UR - http://www.scopus.com/inward/record.url?scp=79551690069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551690069&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2010.12.003
DO - 10.1016/j.bbi.2010.12.003
M3 - Article
C2 - 21156204
AN - SCOPUS:79551690069
SN - 0889-1591
VL - 25
SP - 532
EP - 538
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
IS - 3
ER -